文献速递肝病消化道肿瘤与早癌

肝细胞癌早期检测筛查(HES)算法在退伍军人肝硬化队列中的验证

Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-12-14

本研究在2010至2015年间于退伍军人医疗中心评估的38431例任何病因肝硬化患者中外部验证HES算法。中位随访3.12年期间共发生4804例肝细胞癌。在90%特异性下,HES算法在诊断前6个月内检测肝细胞癌的敏感性为52.56%,而单独甲胎蛋白检测为48.13%,绝对提高4.43%(P < .0005)。

要点

  • 在90%特异性下,HES算法检测肝细胞癌的敏感性为52.56%,单独甲胎蛋白检测为48.13%,绝对提高4.43%(P < .0005)。
  • 每1000次影像学分析检测到的肝细胞癌病例数:HES算法为198.57例,单独甲胎蛋白检测为185.52例,即多检出13例肝细胞癌(P < .0005)。
  • HES算法在肝细胞癌监测中较单独甲胎蛋白检测提供适度但有用的优势。

核心结论

  • HES算法在退伍军人医疗中心评估的任何病因肝硬化患者中验证了肝细胞癌检测效能。
  • 该算法在肝细胞癌监测中较单独甲胎蛋白检测提供适度但有用的优势。

研究设计与样本

  • 在2010年至2015年间于退伍军人医疗中心评估的38431例任何病因肝硬化患者队列中外部验证HES算法。
  • HES算法包含患者当前甲胎蛋白水平、甲胎蛋白变化率、年龄、丙氨酸氨基转移酶水平和血小板计数。

主要发现

  • 中位随访3.12年期间共发生4804例肝细胞癌。
  • 在90%特异性下,HES算法在诊断前6个月内检测肝细胞癌的敏感性为52.56%,单独甲胎蛋白检测为48.13%,绝对提高4.43%(P < .0005)。
  • 每1000次影像学分析检测到的肝细胞癌病例数:HES算法为198.57例,单独甲胎蛋白检测为185.52例,即多检出13例肝细胞癌(P < .0005)。

关键数值与推荐

  • 指南推荐肝硬化患者每6个月接受超声检查进行肝细胞癌监测,可联合或不联合血清甲胎蛋白水平检测。
  • 在肝细胞癌筛查中,阳性结果导致通过计算机断层扫描或磁共振成像进行随访评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Early detection of hepatocellular carcinoma (HCC) through surveillance reduces mortality associated with this cancer. Guidelines recommend HCC surveillance every 6 months for patients with cirrhosis, via ultrasonography, with or without measurement of serum level of alpha fetoprotein (AFP). METHODS: We previously developed and internally validated an HCC early detection screening (HES) algorithm that included patient's current level of AFP, rate of AFP change, age, level of alanine aminotransferase, and platelet count in a department of Veterans affairs (VA) cohort with active hepatitis C virus-related cirrhosis. HES score was associated with 3.84% absolute improvement in sensitivity of detection of HCC compared with AFP alone, at 90% specificity, within 6 months prior to diagnosis of this cancer. We externally validated the HES algorithm in a cohort of 38,431 patients with cirrhosis of any etiology evaluated at a VA medical center from 2010 through 2015. RESULTS: A total of 4804 cases of HCC developed during a median follow-up time of 3.12 years. At 90% specificity, the HES algorithm identified patients with HCC with 52.56% sensitivity, compared to 48.13% sensitivity for the AFP assay alone, within 6 months prior to diagnosis; this was an absolute improvement of 4.43% (P < .0005). In HCC screening, a positive result leads to follow-up evaluation by computed tomography or magnetic resonance imaging. We estimated that the number of HCC cases detected per 1000 imaging analyses was 198.57 for the HES algorithm vs 185.52 for the AFP assay alone, or detection of 13 additional cases of HCC (P < .0005). CONCLUSION: We validated the HES algorithm in detection of HCC in patients with cirrhosis of any etiology evaluated at VA medical centers. The algorithm offers a modest but useful advantage over AFP alone in HCC surveillance.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tayob N, Christie I, Richardson P, et al. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2018. PMID: 30557738. doi:10.1016/j.cgh.2018.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。